by | Jun 1, 2024 | Publications
Blood Cancer J. 2024 May 31;14(1):88. doi: 10.1038/s41408-024-01043-5. ABSTRACT B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis...
by | May 31, 2024 | Publications
Blood Adv. 2024 May 31:bloodadvances.2023012394. doi: 10.1182/bloodadvances.2023012394. Online ahead of print. ABSTRACT As multiple myeloma (MM) poses a formidable therapeutic challenge despite recent progress, exploring novel targets is crucial. Mucosa-associated...
by | May 31, 2024 | Publications
Hematol Oncol. 2024 Jul;42(4):e3290. doi: 10.1002/hon.3290. ABSTRACT The ELOQUENT-3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory...
by | May 31, 2024 | Publications
Clin Hematol Int. 2024 May 6;6(2):46-50. doi: 10.46989/001c.116800. eCollection 2024. ABSTRACT We present the case of a dialyzed patient with relapsed IgA and lambda free light chain multiple myeloma treated with elranatamab. Despite end-stage renal impairment, the...
by | May 31, 2024 | Publications
Clin Hematol Int. 2024 Feb 22;6(1):67-83. doi: 10.46989/001c.92555. eCollection 2024. ABSTRACT BACKGROUND: Globally, multiple myeloma (MM) ranks 24th among the most common cancers. The Middle East and Africa are affected by an increasing trend in MM incidence, owing...
by | May 31, 2024 | Publications
Clin Hematol Int. 2024 Feb 20;6(1):51-58. doi: 10.46989/001c.92984. eCollection 2024. ABSTRACT Approximately 90% of patients with multiple myeloma experience significant pain from osseous involvement during their lifetime. Untreated osseous involvement results in...
